<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>84</patient-age><report-id>US-PFIZER INC-2013028737</report-id><gender>female</gender><reactions><reaction>Allergies to Antihistamines, Diphenhydramine - Type Benadryl; Ibuprofen</reaction><reaction>Dyspnea</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>BENADRYL</drug-name><manufacturer/><ingredients/></drug></drugs><patient-age>84</patient-age><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>psur</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4254114_P31</messagenumb>
		<messagesenderidentifier>PFIZERINC</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151549</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>US-PFIZER INC-2013028737</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="2">No</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-22</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-22</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>2</fulfillexpeditecriteria>
		<companynumb>US-PFIZER INC-2013028737</companynumb>
		<primarysource>
			<reportertitle>Dr</reportertitle>
			<reportergivename>Joseph</reportergivename>
			<reportermiddlename>R</reportermiddlename>
			<reporterfamilyname>Lamb</reporterfamilyname>
			<reporterstreet>1405 Mill Street</reporterstreet>
			<reportercity>New London</reportercity>
			<reporterstate>WI</reporterstate>
			<reporterpostcode>54961</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification code="1">Physician</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>PFIZERINC</senderorganization>
			<senderfamilyname>Head Drug Safety Surveillance</senderfamilyname>
			<senderstreetaddress>150 East 42nd Street</senderstreetaddress>
			<sendercity>New York</sendercity>
			<senderstate>New York</senderstate>
			<senderpostcode>10017</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2127335544</sendertel>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20785</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3019183134</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientonsetage>84</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex code="2">Female</patientsex>
			<reaction>
				<primarysourcereaction>Allergies to Antihistamines, Diphenhydramine - Type Benadryl; Ibuprofen</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Drug allergy</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug hypersensitivity</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Dyspnea</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Dyspnea</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dyspnoea</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>18-989</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Pfizer, Inc.</drugauthorizationholder>
				<drugdosagetext>UNK</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>IBUPROFEN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug allergy</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug allergy</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>BENADRYL</medicinalproduct>
				<drugdosagetext>UNK</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>DIPHENHYDRAMINE HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>This is a spontaneous report from a non clinical study program Pfizer Helpful Answers. A contactable <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>reported that an 84-year old female patient of an unspecified ethnicity started to receive <Semaphore x="696671" class="Medicine" value="Ibuprofen" score="0.97" ID="271165">ibuprofen</Semaphore>, via an unspecified route of administration on an unspecified date at an unspecified dose for an unspecified indication and <Semaphore x="489726" class="Medicine" value="Diphenhydramine Hydrochloride" score="0.74" ID="228795">diphenhydramine hydrochloride </Semaphore>(<Semaphore x="194362" class="Medicine" value="Benadryl" score="0.74" ID="241562">BENADRYL</Semaphore>), via an unspecified route of administration on an unspecified date at an unspecified dose for an unspecified indication. The patient's medical history and concomitant medications were not reported. The patient reported that "he was <Semaphore x="1470824" class="Disease or Finding" value="Allergic Reaction" score="1.00" ID="C114476">allergies </Semaphore>to antihistamines, <Semaphore x="489970" class="Medicine" value="diphenhydrAMINE" score="0.49" ID="257844">diphenhydramine </Semaphore>- type <Semaphore x="194362" class="Medicine" value="Benadryl" score="0.74" ID="241562">benadryl</Semaphore>; <Semaphore x="696671" class="Medicine" value="Ibuprofen" score="0.97" ID="271165">ibuprofen</Semaphore>" (reported as of 15Jan2013) and experienced <Semaphore x="1870759" class="Disease or Finding" value="Dyspnea" score="1.00" ID="C2998">dyspnea </Semaphore>on an unspecified date. The action taken in <Semaphore x="1854566" class="Disease or Finding" value="Disease Response" score="1.00" ID="C50995">response </Semaphore>to the events for <Semaphore x="696671" class="Medicine" value="Ibuprofen" score="0.97" ID="271165">ibuprofen </Semaphore>and <Semaphore x="489726" class="Medicine" value="Diphenhydramine Hydrochloride" score="0.74" ID="228795">diphenhydramine hydrochloride </Semaphore>was unknown. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the events was unknown.Pfizer is Marketing Authorization Holder of <Semaphore x="696671" class="Medicine" value="Ibuprofen" score="0.97" ID="271165">ibuprofen </Semaphore>in the reporter's country. This may be a duplicate report in situations where another Marketing Authorization Holder of <Semaphore x="696671" class="Medicine" value="Ibuprofen" score="0.97" ID="271165">ibuprofen </Semaphore>has submitted the same report to the regulatory authorities.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>